Key Takeaways
- Faricimab and aflibercept showed similar short-term visual and anatomical outcomes in DMO.
- Baseline visual acuity and treatment interval predicted visual response; baseline CST predicted anatomical improvement.
- Early outcomes were driven more by baseline disease features and adherence than by drug choice.
Faricimab and aflibercept 2 mg produced comparable short-term visual and anatomical outcomes in patients with diabetic macular oedema (DMO), according to a study.
The study included 300 patients, with 292 eyes analyzed (191 aflibercept, 101 faricimab). Eyes were treatment-naïve or off therapy for ≥6 months and received a loading phase, with outcomes assessed at four months after the fourth injection using adjusted regression models.
Visual acuity gains were modest and similar between groups. The adjusted mean improvement was +4.2 letters for aflibercept and +4.7 letters for faricimab, with no statistically significant difference between treatments. Baseline visual acuity and treatment interval were significant predictors of functional response, with baseline visual acuity having a substantially greater impact.
Central subfield thickness decreased by an adjusted mean of 95.4 µm in the aflibercept group and 99.8 µm in the faricimab group, with no significant difference observed. Baseline CST was the only independent predictor of anatomical response.
Reference
Chalkiadaki E, Sim SY, Williams O, et al. Real-world early outcomes of intravitreal faricimab 6-mg and aflibercept 2-mg injection in diabetic macular oedema. Br J Ophthalmol. 2026;bjo-2025-328893. doi: 10.1136/bjo-2025-328893. Epub ahead of print. PMID: 42014182.
Related Content
